On October 17, 2016 Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and personalized medicine, reported it will present four new studies at the American Society of Human Genetics Annual Meeting being held Oct. 18-22, 2016 in Vancouver, British Columbia (Press release, Myriad Genetics, OCT 17, 2016, View Source [SID:SID1234515854]). The research being presented highlights the clinical utility of Myriad’s myVision Variant Classification Program and myRisk Hereditary Cancer gene panel test.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Precision medicine is dependent on the accuracy of the information being provided to patients, and Myriad’s myVision is the most advanced variant classification program available to determine whether a patient’s genetic mutation is benign or deleterious," said Johnathan Lancaster, M.D., Ph.D, chief medical officer, Myriad Genetic Laboratories. "At ASH (Free ASH Whitepaper)G, we are excited to present four new studies, which advance the state of the art of genetic testing and meet the scientific needs of researchers and clinicians."

Below is a list of the featured presentations at ASH (Free ASH Whitepaper)G (#ASHG2016):

Platform Presentations

Title: PMS2CL-hybrid Alleles Containing PMS2 Sequence and Other PMS2CL-derived Large Rearrangements: The Importance of Correct Interpretation of Dosage Alteration Analysis in PMS2​.
Presenter: Nanda Singh.
Date: Thursday, October 20, 2016: 12:00 p.m. PT.
Platform: 137, Ballroom C.
Title: NGS Facilitates Identification of Retrotransposon Insertional Mutations in Hereditary Cancer Genes.
Presenter: Yaping Qian.
Date: Thursday, October 20, 2016: 12:45 p.m. PT.
Platform: 156, Room 115.
Poster Presentations

Title: Characterization of TP53 Sequencing Variants Initially Detected in Peripheral Blood Using Next Generation Sequencing Analysis​.
Presenter: Debora Mancini-DiNardo.
Date: Wednesday, October 19, 2016: 2:00 – 3:00 p.m. PT.
Poster: 781W, Exhibit Hall B.
Title: Diagnostic Detection, Characterization & Classification of Partial Single Exon Deletions in Hereditary Cancer Genes​.
Presenter: Benjamin Roa.
Date: Wednesday, October 19, 2016: 2:00 – 3:00 p.m. PT.
Poster: 763W, Exhibit Hall B.
For more information about these presentations, including a complete list of abstracts and presentations, please visit the ASH (Free ASH Whitepaper)G website at View Source